放射性标记 ADME 研究市场报告：2031 年趋势、预测与竞争分析

全球放射性标记ADME检测市场前景光明，为生物製药公司以及政府和学术机构带来机会。预计2025年至2031年期间，全球放射性标记ADME检测市场的复合年增长率将达到12.1%。该市场的主要驱动因素包括药物开发成本的上升、个人化医疗需求的不断增长以及肿瘤学和神经病学研究的不断深入。

Lucintel 预测，按类型划分，C-14 在预测期内将出现高速成长。

从应用角度来看，生物製药公司预计将实现更高的成长。

根据地区，预计亚太地区将在预测期内实现最高成长。

放射性标记ADME检测市场的新趋势

放射性标记 ADME 测试市场正在出现几个新兴趋势，这些趋势受到技术进步、监管变化和不断变化的消费者偏好的推动，正在再形成製药公司进行药物开发的方式，更加註重精准度、效率和个人化治疗。

• 成像技术的进步：PET 和 SPECT 等先进成像技术的使用正在彻底改变放射性标记药物的 ADME 检测。这些技术可以即时、高解析度地成像体内药物的分布，从而更精确地了解药物动力学。这一趋势在肿瘤学和其他治疗领域尤其有益，因为了解药物在组织内的行为对于疗效至关重要。
• 人工智慧与数据分析的融合：人工智慧和机器学习在ADME数据分析中的融合日益凸显。人工智慧主导的演算法可以处理大量资料集，从而识别模式并高精度预测药物行为。这一趋势缩短了药物开发时间，降低了成本，并能够更准确地模拟体内药物交互作用，从而改善治疗效果。
• 重视个人化医疗：个人化医疗日益受到重视，它根据个体的基因特征和代谢行为制定个人化药物治疗方案。放射性标记的ADME研究在这一转变中至关重要，因为它们提供了关于不同个体药物代谢差异的重要数据。这一趋势推动了对更精细的ADME研究的需求，这些研究能够深入了解特定患者群体的药物反应。
• 製药公司与学术机构合作日益增加：製药公司与学术研究机构之间的合作趋势日益增强。此类伙伴关係有助于推动用于ADME检测的新型放射性同位素示踪剂和生物标记物的开发。透过将行业专业知识与学术研究相结合，这些合作加快了创新步伐，并提高了药物开发过程中数据的品质。
• 临床试验外包的成长：在放射性标记ADME检测市场，将临床试验外包给委外研发机构(CRO) 正变得越来越普遍。由于成本效益高且能够获得专业知识，製药公司越来越依赖 CRO 进行 ADME 研究。这一趋势有助于製药公司简化研究流程，专注于核心业务领域，同时利用外部专业知识进行复杂的研究。

人工智慧的整合、放射性示踪剂的进步、个人化医疗、对安全性的关注以及 CRO 的兴起等新兴趋势正在显着改变放射性同位素 ADME 测试市场，提高药物开发的效率、准确性和安全性，缩短新治疗方法的上市时间，并有助于在全球范围内扩大这一市场。

放射性标记ADME检测市场的最新趋势

放射性标记 ADME 测试市场经历了各种发展，反映了药物开发这一关键领域的不断发展，其驱动力包括技术进步、监管变化以及对准确药物动力学数据日益增长的需求。

• 新型放射性同位素示踪剂的开发：新型放射性同位素示踪剂的最新发展趋势正在提升我们研究药物分布、代谢和排泄的能力。这些新型示踪剂提高了灵敏度和特异性，使我们能够更准确地追踪体内的药物。这项进展在肿瘤学和中枢神经系统 (CNS) 疾病中尤其重要，因为了解药物在目标组织中的行为对于疗效至关重要。
• 成像技术的进步：PET-MRI 和 PET-CT 等新型成像技术的整合正在提高放射性同位素 ADME 研究的数据品质。这些混合成像技术提供了药物分布和代谢的详细多维影像，从而更全面地了解药物与人体的相互作用。这项发展正在加快药物开发的步伐，并提高临床试验的准确性。
• 先进检测方法的监管支援：包括美国、德国和日本在内的许多国家正在逐步建立监管框架，以支援使用先进的基于放射性同位素的ADME检测方法。这些法规促进了新药的核准，并为将创新检测技术纳入临床试验提供了简化的途径。这些进展正在增强製药公司对基于放射性同位素的检测方法的信心。
• 药物开发投资的增加：药物研发投资的增加促进了放射性同位素ADME检测的扩展。製药公司正在投入更多资源用于候选药物动力学研究，以期在临床试验前更详细地了解其药物动力学。这一趋势为放射性同位素ADME检测提供者创造了新的机会，使其能够为不断增长的基本客群提供专业的服务。
• 专注于非侵入性检测：人们对放射性同位素ADME检测的非侵入性方法越来越感兴趣，例如基于血液的生物标记和用于监测药物吸收和排泄的可穿戴技术。这些方法提供了一种非侵入性的资料收集方法，既能提高患者的舒适度，又能提供药物行为的宝贵见解。这些进展使ADME检测更加方便患者使用，也使其在临床试验中更具吸引力。

影像技术、放射性追踪剂开发、合作研究计画、监管改进以及CRO服务扩展等最新趋势，都推动了放射性标记ADME检测市场的成长。这些发展正在提高药物检测的效率和准确性，最终加快药物开发的步伐，并确保患者获得更安全的治疗。

目录

第一章执行摘要

2. 全球放射性标记 ADME 测试市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019-2031 年市场趋势与预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球放射性标记 ADME 检测市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球放射性标记 ADME 检测市场（按类型）
  • C-14
  • H-3
  • 其他的
• 全球放射性标记ADME检测市场（依应用）
  • 生物製药公司
  • 政府和学术机构
  • 其他的

第四章 2019 - 2031 年各地区市场趋势及预测分析

• 全球放射性标记ADME检测市场（按地区）
• 北美放射性标记ADME检测市场
• 欧洲放射性标记ADME检测市场
• 亚太地区放射性标记ADME检测市场
• 世界其他地区放射性标记ADME检测市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球放射性标记 ADME 测试市场成长机会（按类型）
  • 全球放射性标记 ADME 检测市场的成长机会（按应用）
  • 全球放射性标记 ADME 检测市场各区域成长机会
• 全球放射性标记ADME检测市场的新趋势
• 战略分析
  • 新产品开发
  • 全球放射性标记ADME检测市场产能扩张
  • 全球放射性标记 ADME 检测市场合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Charles River
• Eurofins Scientific
• Evotec
• Labcorp
• Sekisui Medical
• Xenotech（Bioivt）
• Qps
• Bioduro-Sundia
• Quotient Sciences
• Chelatec

The future of the global radiolabelled ADME studies market looks promising with opportunities in the biopharmaceutical company and government and academic institute markets. The global radiolabelled ADME studies market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are the increasing drug development cost, rising demand for personalized medicine, and increased research in oncology and neurology.

Lucintel forecasts that, within the type category, C-14 is expected to witness higher growth over the forecast period.

Within the application category, a biopharmaceutical company is expected to witness higher growth.

In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market is witnessing several emerging trends driven by technological advancements, regulatory changes, and evolving consumer preferences. These trends are reshaping how pharmaceutical companies approach drug development, with a greater focus on precision, efficiency, and personalized treatments.

• Advancement of Imaging Technologies: The use of advanced imaging technologies like PET and SPECT is revolutionizing Radiolabelled ADME studies. These techniques allow for real-time, high-resolution imaging of drug distribution within the body, offering more accurate insights into pharmacokinetics. This trend is particularly beneficial in oncology and other therapeutic areas where understanding drug behavior in tissues is critical for treatment efficacy.
• Integration of Artificial Intelligence in Data Analysis: The integration of AI and ML in analyzing ADME data is becoming increasingly prominent. AI-driven algorithms can process large datasets to identify patterns and predict drug behaviors with high accuracy. This trend is enhancing drug development timelines, reducing costs, and enabling more precise modeling of drug interactions in the body, leading to improved therapeutic outcomes.
• Focus on Personalized Medicine: There is a growing emphasis on personalized medicine, which tailors drug treatments based on individual genetic profiles and metabolic behaviors. Radiolabelled ADME studies are pivotal in this shift, as they provide critical data on how different individuals metabolize drugs. This trend is driving the demand for more sophisticated ADME studies that can offer insights into drug responses for specific patient populations.
• Increased Collaboration of Pharma and Academic Institutions: Increased collaborations between pharmaceutical companies and academic research institutions are a growing trend. These partnerships help in advancing the development of new radiolabelled tracers and biomarkers for ADME studies. By combining industry expertise with academic research, these collaborations accelerate the pace of innovation and improve the quality of data generated in drug development.
• Growth of Outsourcing in Clinical Trials: The outsourcing of clinical trials to contract research organizations (CROs) is becoming more common in the radiolabelled ADME studies market. Pharmaceutical companies are increasingly relying on CROs for conducting ADME studies due to cost-effectiveness and access to specialized knowledge. This trend is helping pharmaceutical companies streamline their research processes and focus on core business areas, while leveraging external expertise in conducting complex studies.

Emerging trends like AI integration, radiotracer advancements, personalized medicine, a focus on safety, and the rise of CROs are significantly reshaping the radiolabelled ADME studies market. These trends are improving efficiency, precision, and the overall safety of drug development, driving faster time-to-market for new treatments and contributing to the expansion of this market globally.

Recent Developments in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market has seen a variety of developments, reflecting the continuous evolution of this critical area of drug development. These developments are driven by technological advancements, regulatory changes, and the increasing need for accurate pharmacokinetic data.

• Development of New Radiolabelled Tracers: Recent advancements in the development of new radiolabelled tracers have enhanced the ability to study drug distribution, metabolism, and excretion. These new tracers offer improved sensitivity and specificity, enabling more precise tracking of drugs within the body. This development is particularly useful in oncology and central nervous system (CNS) disorders, where understanding drug behavior in targeted tissues is crucial for treatment efficacy.
• Advances in Imaging Techniques: The integration of novel imaging technologies such as PET-MRI and PET-CT is improving the quality of data in Radiolabelled ADME studies. These hybrid imaging techniques provide detailed, multi-dimensional images of drug distribution and metabolism, offering a more comprehensive view of how drugs interact with the human body. This development is accelerating the pace of drug development and improving the accuracy of clinical trials.
• Regulatory Support for Advanced Testing Methods: Many countries, including the United States, Germany, and Japan, are increasingly adopting regulatory frameworks that support the use of advanced radiolabelled ADME testing methods. These regulations facilitate the approval of new drugs and provide a streamlined pathway for integrating innovative testing technologies into clinical trials. This development is fostering greater confidence in radiolabelled studies among pharmaceutical companies.
• Growing Investment in Drug Development: Increased investment in pharmaceutical R&D is contributing to the expansion of Radiolabelled ADME studies. Pharmaceutical companies are allocating more resources to studying the pharmacokinetics of new drug candidates, as they seek to understand their behavior more thoroughly before clinical trials. This trend is creating new opportunities for radiolabelled ADME study providers to offer specialized services to a growing client base.
• Focus on Non-Invasive Testing: There is a growing interest in non-invasive testing methods for Radiolabelled ADME studies, including blood-based biomarkers and wearable technologies that monitor drug absorption and excretion. These methods provide a less invasive approach to collecting data, improving patient comfort while providing valuable insights into drug behavior. This development is making ADME studies more patient-friendly and increasing their appeal in clinical trials.

Recent developments such as technological advancements in imaging, radiotracer development, collaborative research initiatives, regulatory improvements, and the expansion of CRO services are all contributing to the growth of the radiolabelled ADME studies market. These developments are improving the efficiency and accuracy of drug testing, ultimately accelerating the pace of drug development and ensuring safer treatments for patients.

Strategic Growth Opportunities in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market offers significant strategic growth opportunities, particularly in applications related to drug development, precision medicine, and diagnostic imaging. These opportunities are being driven by the demand for more detailed pharmacokinetic data and the increasing use of advanced technologies in drug testing.

• Expansion in Oncology Drug Development: The growing focus on oncology drug development presents a major opportunity for Radiolabelled ADME studies. As cancer treatments become more targeted and personalized, radiolabelled studies are providing valuable insights into the distribution of therapeutic agents within tumor tissues. This application is enabling pharmaceutical companies to develop more effective and precise treatments, improving patient outcomes.
• Advancements in CNS Drug Development: The development of drugs targeting central nervous system (CNS) disorders is another area where Radiolabelled ADME studies are playing a critical role. These studies help researchers understand how drugs cross the blood-brain barrier and interact with brain tissues, providing crucial data for developing effective treatments for neurological diseases. This growth opportunity is attracting investments in radiolabelled ADME testing services.
• Personalized Medicine Applications: As personalized medicine continues to gain momentum, the demand for radiolabelled ADME studies tailored to individual genetic profiles is growing. These studies provide insights into how different individuals metabolize drugs, allowing for the development of more targeted therapies. The application of Radiolabelled ADME studies in personalized medicine is a key growth opportunity for the market.
• Technological Integration with Artificial Intelligence: The integration of AI and machine learning in analyzing Radiolabelled ADME study data is a significant growth opportunity. AI-driven data analysis can enhance the accuracy and efficiency of these studies, providing pharmaceutical companies with quicker insights into drug behavior. This technological advancement is making Radiolabelled ADME studies more cost-effective and faster, driving further adoption in drug development.
• Outsourcing of Radiolabelled ADME Studies: Outsourcing Radiolabelled ADME studies to contract research organizations (CROs) is becoming increasingly popular as pharmaceutical companies look to reduce costs and gain access to specialized expertise. This trend offers growth opportunities for CROs and testing service providers, allowing them to expand their service offerings and cater to a growing global market.

The radiolabelled ADME studies market is experiencing growth across multiple applications, particularly in oncology, neuroscience, drug safety, biopharmaceuticals, and early-stage drug development. These strategic growth opportunities will drive innovation in the market, ensuring more efficient and targeted therapies for patients and accelerating drug development timelines.

Radiolabelled ADME Studies Market Driver and Challenges

The radiolabelled ADME studies market is influenced by various technological, economic, and regulatory factors. These drivers and challenges significantly shape the market's development and the strategic decisions made by pharmaceutical companies and research organizations.

The factors responsible for driving the radiolabelled ADME studies market include:

1. Technological Advancements in Imaging and Tracer Development: The continuous advancement in imaging technologies like PET, SPECT, and MRI is a key driver of growth in the radiolabelled ADME studies market. These technologies enable more accurate and detailed tracking of drug behavior, making ADME studies more effective in assessing drug pharmacokinetics.

2. Increase in Drug Development Activities: The growing global pharmaceutical R&D activities are driving the demand for Radiolabelled ADME studies. As pharmaceutical companies focus on developing new and innovative therapies, the need for precise pharmacokinetic data to support drug approval processes is growing, driving the market for ADME testing services.

3. Government Support and Regulatory Frameworks: In many countries, government policies and regulatory support for the pharmaceutical and biotechnology sectors are driving growth in the radiolabelled ADME studies market. Regulatory frameworks that encourage the use of advanced testing methods are helping to accelerate the approval of new drugs and improve the quality of data obtained from ADME studies.

4. Growth in Precision Medicine: The rise of precision medicine is a significant driver of the radiolabelled ADME studies market. These studies are crucial for understanding how different patients metabolize drugs based on their genetic profiles, which is essential for developing personalized treatment options.

5. Global Expansion of Pharmaceutical Companies: As pharmaceutical companies expand their global presence, there is a growing demand for Radiolabelled ADME studies to understand drug behavior in diverse patient populations. This expansion is driving the market's growth by requiring more comprehensive and accurate data for drug development across multiple regions.

Challenges in the radiolabelled ADME studies market are:

1. High Costs of Radiolabelled ADME Studies: The high cost of conducting Radiolabelled ADME studies is a major challenge for pharmaceutical companies, especially for smaller firms with limited research budgets. The expense of producing radiolabelled tracers and conducting imaging studies can be prohibitive, limiting the number of studies conducted.

2. Regulatory Complexity and Approval Delays: The regulatory landscape for Radiolabelled ADME studies is complex, with varying requirements across different regions. These regulatory hurdles can lead to delays in study approval and increase the time and cost associated with bringing new drugs to market.

3. Limited Availability of Skilled Professionals: The specialized nature of Radiolabelled ADME studies requires skilled professionals, including radiochemists, pharmacologists, and imaging experts. The limited availability of qualified professionals in certain regions can create challenges in meeting the demand for these studies.

4. Ethical Concerns with Radiolabelled Testing: Ethical concerns related to the use of radioactive substances in human testing can pose challenges for Radiolabelled ADME studies. Public perceptions of the risks associated with radioactive materials may lead to regulatory scrutiny and limit the acceptance of these testing methods.

5. Technological Challenges in Imaging and Data Analysis: Despite advancements, challenges remain in the application of imaging technologies to Radiolabelled ADME studies. The accuracy of data obtained from imaging devices can be influenced by several factors, including the sensitivity of the tracers used and the ability to capture real-time data. These technological challenges can limit the effectiveness of Radiolabelled ADME studies and hinder market growth.

The radiolabelled ADME studies market is driven by advancements in technology, personalized medicine, and the growing demand for drug safety and regulatory compliance. However, challenges such as high costs, regulatory hurdles, and the limited availability of radiolabelled compounds must be addressed for the market to continue its growth.

List of Radiolabelled ADME Studies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiolabelled ADME studies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiolabelled ADME studies companies profiled in this report include-

• Charles River
• Eurofins Scientific
• Evotec
• Labcorp
• Sekisui Medical
• Xenotech (Bioivt)
• Qps
• Bioduro-Sundia
• Quotient Sciences
• Chelatec

Radiolabelled ADME Studies Market by Segment

The study includes a forecast for the global radiolabelled ADME studies market by type, application, and region.

Radiolabelled ADME Studies Market by Type [Value from 2019 to 2031]:

• C-14
• H-3
• Others

Radiolabelled ADME Studies Market by Application [Value from 2019 to 2031]:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Others

Radiolabelled ADME Studies Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiolabelled ADME Studies Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. It highlights recent developments by major radiolabelled ADME studies producers in key regions: the USA, China, India, Japan, and Germany.

• United States: The U.S. has seen notable progress in the radiolabelled ADME studies market with advancements in imaging technologies such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). These innovations have enabled more accurate and real-time tracking of drug distribution within the human body, providing enhanced data for pharmaceutical research and clinical trials. Additionally, the adoption of artificial intelligence (AI) and machine learning (ML) in analyzing ADME data has further advanced drug development processes, making them more efficient and precise.
• China: The Chinese radiolabelled ADME studies market is growing rapidly, fueled by significant investments in research and technological advancements in medical imaging. The Chinese government's support for biotechnology and healthcare initiatives has led to an expansion of facilities focused on radiolabelled compound testing. Moreover, collaborations between Chinese research institutes and global pharmaceutical companies have strengthened the research capabilities in the country, allowing for better drug development processes and improved understanding of pharmacokinetics.
• Germany: In Germany, the focus on precision medicine has driven the growth of the radiolabelled ADME studies market. Technological advancements in PET and SPECT imaging technologies have allowed for more detailed studies on drug metabolism and tissue distribution. Furthermore, Germany's regulatory framework is conducive to the adoption of innovative testing methods, encouraging pharmaceutical companies to utilize radiolabelled studies in their drug development pipeline. The country's well-established pharmaceutical and biotechnology industries have also spurred further research into this area.
• India: India has emerged as an important player in the radiolabelled ADME studies market, driven by increasing pharmaceutical R&D activities and an expanding healthcare infrastructure. The country has become a hub for clinical trials, with numerous international pharmaceutical companies conducting radiolabelled studies to understand drug metabolism and excretion. India's cost-effective research and development environment, combined with its growing expertise in pharmacokinetics, has made it an attractive location for global pharmaceutical companies.
• Japan: The Japanese radiolabelled ADME studies market has benefited from its advanced technological infrastructure and robust pharmaceutical industry. Japan has been a leader in developing new radiolabelled tracers and biomarkers for use in ADME studies. The country's regulatory support for new drug development and its commitment to advancing healthcare technologies have led to increased collaborations between academic institutions and pharmaceutical companies. Japan is also seeing growth in the demand for precision medicine, which further drives the need for more accurate ADME data.

Features of the Global Radiolabelled ADME Studies Market

Market Size Estimates: Radiolabelled ADME studies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Radiolabelled ADME studies market size by type, application, and region in terms of value ($B).

Regional Analysis: Radiolabelled ADME studies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the radiolabelled ADME studies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiolabelled ADME studies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiolabelled ADME studies market by type (C-14, H-3, and others), application (biopharmaceutical companies, government and academic institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiolabelled ADME Studies Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Radiolabelled ADME Studies Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Radiolabelled ADME Studies Market by Type
  • 3.3.1: C-14
  • 3.3.2: H-3
  • 3.3.3: Others
• 3.4: Global Radiolabelled ADME Studies Market by Application
  • 3.4.1: Biopharmaceutical Companies
  • 3.4.2: Government and Academic Institutes
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Radiolabelled ADME Studies Market by Region
• 4.2: North American Radiolabelled ADME Studies Market
  • 4.2.1: North American Market by Type: C-14, H-3, and Others
  • 4.2.2: North American Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.3: European Radiolabelled ADME Studies Market
  • 4.3.1: European Market by Type: C-14, H-3, and Others
  • 4.3.2: European Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.4: APAC Radiolabelled ADME Studies Market
  • 4.4.1: APAC Market by Type: C-14, H-3, and Others
  • 4.4.2: APAC Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.5: ROW Radiolabelled ADME Studies Market
  • 4.5.1: ROW Market by Type: C-14, H-3, and Others
  • 4.5.2: ROW Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Type
  • 6.1.2: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Application
  • 6.1.3: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Region
• 6.2: Emerging Trends in the Global Radiolabelled ADME Studies Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiolabelled ADME Studies Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiolabelled ADME Studies Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Charles River
• 7.2: Eurofins Scientific
• 7.3: Evotec
• 7.4: Labcorp
• 7.5: Sekisui Medical
• 7.6: Xenotech (Bioivt)
• 7.7: Qps
• 7.8: Bioduro-Sundia
• 7.9: Quotient Sciences
• 7.10: Chelatec